Ibrutinib + LY3214996
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Lymphocytic Leukemia
Conditions
Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Trial Timeline
Feb 3, 2020 → Feb 3, 2020
NCT ID
NCT04043845About Ibrutinib + LY3214996
Ibrutinib + LY3214996 is a phase 1 stage product being developed by Eli Lilly for Chronic Lymphocytic Leukemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04043845. Target conditions include Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04043845 | Phase 1 | Withdrawn |
Competing Products
20 competing products in Chronic Lymphocytic Leukemia